Evidence map›Paper›PMID 27122574›Full record

ArticleJournal of virology2016

Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies.

Benjamin von Bredow, Juan F Arias, Lisa N Heyer, Brian Moldt, Khoa Le, James E Robinson, Susan Zolla-Pazner, Dennis R Burton, David T Evans

Open access · hybridAbstract readComparative Study
In one paragraph

Article in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers.

0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed
9.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

103 citing papers in PubMed, 126 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

43 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Benjamin von BredowDepartment of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin, USA.
Juan F AriasDepartment of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin, USA.
Lisa N HeyerNew England Primate Research Center, Harvard Medical School, Southborough, Massachusetts, USA.
Brian MoldtDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA.
Khoa LeDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA.
James E RobinsonDepartment of Pediatrics, Tulane University School of Medicine, New Orleans, Louisiana, USA.
Susan Zolla-PaznerDivision of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID http://orcid.org/0000-0002-0750-2666
Dennis R BurtonDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA.
David T EvansDepartment of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin, USA dtevans2@wisc.edu.
Scripps Research Institute · USUniversity of Wisconsin–Madison · USIcahn School of Medicine at Mount Sinai · USNew England Biolabs (United States) · USTulane University · US

Funding

WNPRC Supplemental Request for Nonhuman Primate Enclosures to Equip HIV/AIDS-Related Research FacilitiesP51OD011106 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI Dorota A. Grejner-Brzezinska · 2012 to 2026
$150.7M
Support Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI GODZIK, ADAM · 2012 to 2018
$131.5M
Antibody Effector Function in Protection Against HIV-1R37AI055332 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2009 to 2018
$9.7M
Sustained antibody delivery for durable suppression of immunodeficiency virus replicationR01AI121135 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI David T Evans · 2015 to 2026
$6.9M
ANTIBODY EFFECTOR FUNCTION IN PROTECTION AGAINST HIV-1R01AI055332 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2003 to 2007
$3.8M
KIR and MHC Class I Immunogenetics in SIV InfectionR01AI095098 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI EVANS, DAVID T · 2012 to 2016
$2.7M
Lentiviral Resistance to TetherinR01AI098485 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI EVANS, DAVID T · 2012 to 2016
$2.2M
NIAID NIH HHS R01 AI055332NIAID NIH HHS R01 AI095098NIAID NIH HHS R01 AI098485NIAID NIH HHS R01 AI121135NIAID NIH HHS R37 AI055332NIAID NIH HHS UM1 AI100663NIH HHS P51 OD011106
6 · The paper itself

Abstract

unlabelledAlthough antibodies to the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein have been studied extensively for their ability to block viral infectivity, little data are currently available on nonneutralizing functions of these antibodies, such as their ability to eliminate virus-infected cells by antibody-dependent cell-mediated cytotoxicity (ADCC). HIV-1 Env-specific antibodies of diverse specificities, including potent broadly neutralizing and nonneutralizing antibodies, were therefore tested for ADCC against cells infected with a lab-adapted HIV-1 isolate (HIV-1NL4-3), a primary HIV-1 isolate (HIV-1JR-FL), and a simian-human immunodeficiency virus (SHIV) adapted for pathogenic infection of rhesus macaques (SHIVAD8-EO). In accordance with the sensitivity of these viruses to neutralization, HIV-1NL4-3-infected cells were considerably more sensitive to ADCC, both in terms of the number of antibodies and magnitude of responses, than cells infected with HIV-1JR-FL or SHIVAD8-EO ADCC activity generally correlated with antibody binding to Env on the surfaces of virus-infected cells and with viral neutralization; however, neutralization was not always predictive of ADCC, as instances of ADCC in the absence of detectable neutralization, and vice versa, were observed. These results reveal incomplete overlap in the specificities of antibodies that mediate these antiviral activities and provide insights into the relationship between ADCC and neutralization important for the development of antibody-based vaccines and therapies for combating HIV-1 infection. IMPORTANCE: This study provides fundamental insights into the relationship between antibody-dependent cell-mediated cytotoxicity (ADCC) and virus neutralization that may help to guide the development of antibody-based vaccines and immunotherapies for the prevention and treatment of HIV-1 infection.

Indexed as

Antibody-Dependent Cell CytotoxicityAIDS VaccinesAnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibody SpecificityBinding Sites, Antibodyenv Gene Products, Human Immunodeficiency VirusHEK293 CellsHIV-1HIV AntibodiesHIV InfectionsHumansMacaca mulattaNeutralization TestsSimian Immunodeficiency VirusAIDS VaccinesAntibodies, MonoclonalAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusHIV Antibodies

Identifiers

PMID27122574
PMCPMC4907221
OpenAlexW2343368748

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.